GLP-1 Blood Work Monitoring: What to Track While on Semaglutide or Tirzepatide in 2026

You started a GLP-1. The scale is moving. But what's happening inside?

Semaglutide and Tirzepatide are not supplements. They alter glucose metabolism, appetite signaling, gastric motility, and in some cases, lean mass retention. Your bloodwork changes while you're on them — and not all of those changes are obvious from how you feel.

Here's exactly what to monitor, when to test, and why each marker matters if you're running a GLP-1 protocol in 2026.

Why GLP-1 Medications Demand Active Lab Monitoring

Most people start Semaglutide or Tirzepatide through a telehealth platform, get their prescription, and go months without a single blood draw. That's a problem.

GLP-1 receptor agonists work by mimicking incretin hormones — affecting insulin secretion, glucagon suppression, and gastric emptying. Tirzepatide adds a GIP receptor agonist component, which broadens its metabolic effects. Both medications can shift markers you wouldn't expect: thyroid function, kidney filtration, liver enzymes — especially during rapid weight loss.

Monitoring isn't optional. It's how you confirm the medication is doing what you think it's doing, and not quietly creating problems somewhere else.

The Core Markers to Monitor on a GLP-1 Protocol

Fasting Glucose and HbA1c

The obvious starting point. GLP-1 medications lower fasting glucose and improve insulin sensitivity. You want fasting glucose trending toward the 70–99 mg/dL range and HbA1c below 5.7% if metabolic normalization is the goal.

If you're not diabetic and your fasting glucose was already normal, watch for hypoglycemia risk — particularly if you're also running a significant caloric deficit. Tirzepatide's dual mechanism makes this more relevant than Semaglutide alone.

Fasting Insulin and HOMA-IR

Fasting glucose tells you where blood sugar sits at rest. Fasting insulin tells you how hard your pancreas is working to hold it there. HOMA-IR, calculated from both, gives you a composite picture of insulin resistance.

These markers often improve substantially on GLP-1 therapy. Tracking them confirms the medication is working at a metabolic level — not just producing weight loss through caloric restriction.

Comprehensive Metabolic Panel (CMP)

This covers kidney function (creatinine, BUN, eGFR), liver enzymes (ALT, AST), electrolytes, and total protein. All of it matters during GLP-1 use.

Rapid weight loss can temporarily elevate liver enzymes as fat mobilizes from the liver. Reduced intake can throw off electrolyte balance. Kidney function deserves attention because GLP-1 medications are cleared renally, and dehydration from suppressed appetite compounds that risk.

Lipid Panel and ApoB

Weight loss generally improves lipid profiles, but the specific trajectory matters. Total cholesterol, LDL, HDL, and triglycerides all shift during GLP-1 therapy — how much depends on your baseline, your diet, and how well you're preserving lean mass.

ApoB is a more precise cardiovascular risk marker than LDL alone. It counts atherogenic particles, not just their cholesterol content. If cardiovascular or metabolic risk reduction is part of your rationale for being on a GLP-1, ApoB is what tells you whether the intervention is actually moving the needle on particle burden.

Thyroid Panel: TSH, Free T3, Free T4

GLP-1 receptor agonists have a known association with thyroid C-cell stimulation in animal models. In humans, the clinical significance is still being studied, but thyroid monitoring is standard practice — especially for anyone with a personal or family history of medullary thyroid carcinoma.

Beyond the safety angle, thyroid function directly affects metabolic rate, energy, and body composition. If your TSH is elevated and Free T3 is low while you're on a GLP-1, you may be losing more lean mass and seeing slower fat loss than expected — not because the medication isn't working, but because your thyroid is suppressing your metabolic baseline.

Lean Mass Indicators: IGF-1 and Total Testosterone

This is where most GLP-1 monitoring protocols fall short.

Rapid weight loss in a caloric deficit suppresses IGF-1 and can lower total and free testosterone. For men on TRT or anyone prioritizing body composition, this is not a minor detail. You can lose significant muscle during a GLP-1 protocol if you're not tracking the hormonal environment that governs protein synthesis.

IGF-1 reflects growth hormone axis activity and serves as a proxy for anabolic signaling. Total testosterone, free testosterone, SHBG, LH, and FSH tell you whether the HPG axis is staying intact during the cut. If testosterone is dropping alongside your weight, the protocol needs adjustment — more protein, more training volume, a reassessment of your deficit, or all three.

Inflammatory Markers: hsCRP and GlycA

GLP-1 medications have documented anti-inflammatory effects. Both hsCRP and GlycA should trend downward during effective therapy.

If they're not moving, that's data. It may mean dietary quality, sleep, or other inflammatory inputs are offsetting what the medication is doing.

Complete Blood Count (CBC)

Restricted eating over time can lead to micronutrient deficiencies. A CBC flags early signs of anemia, which can show up as fatigue that gets misattributed to the medication or the deficit. If you're seeing unexplained performance drops or persistent low energy, iron, ferritin, and B12 are worth adding alongside the CBC.

When to Test: A Practical Timeline

Before starting: Establish your baseline. Fasting glucose, HbA1c, fasting insulin, CMP, lipids, ApoB, thyroid panel, CBC, and a full hormone panel. Without a baseline, every result you get later is context-free.

At 8–12 weeks: First follow-up draw. You've likely titrated to a therapeutic dose by now. Check glucose markers, liver enzymes, kidney function, and lipids. Early red flags tend to surface here.

At 6 months: Comprehensive reassessment. Add IGF-1, testosterone panel, hsCRP, GlycA, and ferritin if they weren't in your baseline. This is when lean mass loss becomes measurable and when hormonal suppression from a prolonged caloric deficit starts showing up in labs.

Ongoing: Every 3–6 months depending on dose, goals, and whether you're also managing TRT or other protocols.

What a GLP-1 Monitoring Panel Should Actually Include

A standard annual physical won't cover this. Most primary care labs ordered alongside GLP-1 prescriptions check glucose and maybe a CMP. That's not enough.

A proper monitoring panel should include:

• Fasting glucose, HbA1c, fasting insulin
• CMP (kidney and liver function, electrolytes)
• Lipid panel with ApoB
• TSH, Free T3, Free T4
• CBC with differential
• Ferritin, B12
• hsCRP or GlycA
• Total testosterone, free testosterone, SHBG, LH, FSH
• IGF-1
• Estradiol (relevant for women and men on TRT)

That's the floor — not an exhaustive list, but the minimum for anyone taking a GLP-1 seriously.

At Anabolic Insights, you can order panels covering all of these markers without a doctor's appointment, a subscription, or a referral. The Advanced Men's Panel and Complete Women's Panel both include the hormone, metabolic, thyroid, and inflammatory markers relevant to GLP-1 monitoring. No annual commitment required.

If you're already on Semaglutide ($159) or Tirzepatide ($199), the lab work that should accompany those protocols is available on the same platform, à la carte.

The Lean Mass Problem Nobody Talks About

GLP-1 medications produce weight loss. But weight is not the same as fat mass.

Studies consistently show that a meaningful percentage of weight lost on GLP-1 therapy comes from lean mass. The exact ratio depends on protein intake, resistance training, and the hormonal environment — specifically testosterone and IGF-1.

If your testosterone drops from 650 ng/dL to 380 ng/dL over six months on a GLP-1 and you're not testing, you won't know why your strength is declining, your recovery is suffering, or your body composition isn't tracking the way the scale suggests it should.

That's the gap between weight loss and body recomposition. Labs close it.

FAQs

What blood tests should I get before starting Semaglutide or Tirzepatide? At minimum: fasting glucose, HbA1c, fasting insulin, a comprehensive metabolic panel, lipid panel with ApoB, thyroid panel (TSH, Free T3, Free T4), CBC, and a full hormone panel including testosterone, SHBG, LH, FSH, and IGF-1. This baseline is what makes every follow-up result meaningful.

How often should I get blood work while on a GLP-1? Every 8–12 weeks during titration, then every 3–6 months once you're at a stable dose. More frequent testing makes sense if you're also managing TRT, have existing metabolic conditions, or are running an aggressive caloric deficit.

Can Semaglutide or Tirzepatide affect testosterone levels? Yes, indirectly. Significant caloric restriction and rapid weight loss can suppress LH, FSH, and total testosterone. Tracking these markers during a GLP-1 protocol matters for anyone — men or women — who cares about body composition and hormonal health.

Why does thyroid function need to be monitored on a GLP-1? GLP-1 receptor agonists have shown thyroid C-cell stimulation in animal studies, making thyroid monitoring standard safety practice. Beyond safety, thyroid function directly affects metabolic rate and body composition — so it's relevant on both fronts.

What is ApoB and why does it matter more than LDL on a GLP-1? ApoB measures the number of atherogenic lipoprotein particles in your blood. LDL measures their cholesterol content. Particle count is a stronger predictor of cardiovascular risk than cholesterol concentration. If cardiovascular risk reduction is part of your reason for being on a GLP-1, ApoB is the marker that tells you whether it's actually working.

Can I order GLP-1 monitoring labs without a doctor's appointment? Yes. Direct-to-consumer lab platforms let you order what you need without a referral or insurance. Anabolic Insights offers tiered panels covering the full range of GLP-1 monitoring markers, with à la carte panel options.

What happens if my liver enzymes are elevated while on a GLP-1? Mild, transient elevation in ALT or AST can occur during rapid fat mobilization — particularly in people with pre-existing fatty liver. Significant or sustained elevation warrants a conversation with your provider. This is exactly why a baseline CMP before starting, and follow-up labs at 8–12 weeks, isn't optional.

Start with a Baseline. Everything Else Follows.

You wouldn't run a 12-week training block without tracking your lifts. Same logic applies here. GLP-1 medications are effective, but they operate inside a complex physiological system. Knowing what's changing — and what isn't — is the difference between a protocol that works and one that quietly costs you lean mass, hormonal health, or metabolic function.

Your bloodwork should not wait for your next annual physical. Order your panel at Anabolic Insights.